From: Concomitant 177Lu-DOTATATE and capecitabine therapy in malignant paragangliomas
Variables | Baseline QLQ | Post-therapy QLQ | P value |
---|---|---|---|
Pain | 51.8 ± 22.7 | 26.8 ± 20.8 | 0.001 |
Swallowing | 31.4 ± 33.3 | 17.31 ± 16.6 | 0.786 |
Senses (taste and smell) | 11.1 ± 24.9 | 10.1 ± 24.3 | 0.903 |
Speech | 34.5 ± 22.2 | 30.2 ± 22.2 | 0.312 |
Social eating | 31.1 ± 33.3 | 16.6 ± 16.6 | 0.107 |
Social contact | 29.6 ± 23.7 | 19.6 ± 19.5 | 0.175 |
Sexuality | 28.7 ± 25 | 31.4 ± 16.6 | 0.705 |
Teeth | 25.9 ± 33.3 | 16.6 ± 0.1 | 0.244 |
Opening mouth | 51.2 ± 50 | 25.6 ± 33.3 | 0.158 |
Dry mouth | 17.9 ± 17.2 | 10.25 ± 16 | 0.251 |
Sticky saliva | 11.1 ± 16 | 3.7 ± 10.7 | 0.112 |
Coughing | 38.4 ± 18.4 | 20.5 ± 21.6 | 0.002 |
Felt ill | 43.5 ± 33.3 | 25.6 ± 33.3 | 0.031 |
Painkiller | 83.3 ± 38.3 | 18.5 ± 17 | < 0.0001 |
Nutritional supplement | 38.4 ± 50.6 | 5.1 ± 12.1 | 0.062 |